# A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

> **NCT05462756** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 730 (actual)

## Conditions studied

- Type 2 Diabetes
- Type 2 Diabetes Treated With Insulin

## Interventions

- **DRUG:** Insulin Efsitora Alfa
- **DRUG:** Insulin Lispro (U100)
- **DRUG:** Insulin Glargine (U100)

## Key facts

- **NCT ID:** NCT05462756
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-11
- **Primary completion:** 2024-02-27
- **Final completion:** 2024-02-27
- **Target enrollment:** 730 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05462756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05462756, "A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05462756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*